TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00959608

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Think Health! program
Description: Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Think Health! program
Description: Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Plus program
Description: 15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
Study: NCT00466063

Intervention type: DRUG
Intervention: Deferasirox
Study: NCT04228263

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: 400mg

Intervention type: DRUG
Group type: OTHER
Intervention: Folic Acid
Description: 5 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Folic Acid
Description: 5 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Low-dose aspirin
Description: 75 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Low-dose aspirin
Description: 75 mg
Study: NCT01784991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 1mg of Hydromorphone at timepoint 0 and 1 mg of hydromorphone at 15 min timepoint.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
Study: NCT00647296

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2 tablets taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 2 tablets taken orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole 50 mg/day
Description: Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole 50 mg/day
Description: Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole 150 mg/day
Description: Dexpramipexole: 2 x 37.5 mg tablets taken orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole 300 mg/day
Description: Dexpramipexole: 2 x 75 mg tablets taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole 300 mg/day
Description: Dexpramipexole: 2 x 75 mg tablets taken orally twice daily
Study: NCT03140514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rejection treatment according to clinical standard-of-care
Description: Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
Study: NCT01548547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation-based mastery learning
Description: Hands-on coached deliberate practice on a simulator. Training until mastery achieved.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based mastery learning
Description: Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
Study: NCT00798200

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise program
Description: All exercise programs will include endurance and strength exercises.
Study: NCT02249416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV) low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) low
Description: Norvir®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV) high
Description: Retrovir®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Study: NCT01017185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF10
Study: NCT03728465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
Study: NCT03353675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4010
Description: 1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360 mg IV administration every 3 weeks
Study: NCT04261556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS + CCT
Description: 40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal transcranial direct current stimulation (tDCS).~In the first 20 min of the 40 min-intervention, real anodal tDCS and CCT will be provided simultaneously.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS + CCT
Description: 40 min/day of computerised cognitive training (CCT) + 20 min/day of apparent (sham) tDCS.~In the first 20 min of the 40 min-intervention, sham tDCS and CCT will be provided simultaneously.
Study: NCT00707785

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 50,000 IU of Vitamin A 50,000 IU of vegetable oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: 50,000 IU of Vitamin A 50,000 IU of vegetable oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 50,000 IU of Vitamin A 50,000 IU of vegetable oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: 50,000 IU of Vitamin A 50,000 IU of vegetable oil
Study: NCT02106000

Intervention type: DEVICE
Intervention: Inhalation profile recorder
Description: Up to three inhalation profiles will be recorded whilst inhaling with maximal effort

Intervention type: DEVICE
Intervention: Inhalation profile recorder
Description: Up to three inhalation profiles will be recorded whilst inhaling with maximal effort
Study: NCT00601835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine
Description: 0.5 mL, Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine
Description: 0.5 mL, Intramuscular, Single dose
Study: NCT05581017

Intervention type: PROCEDURE
Intervention: Preoperative biliary drainage
Description: Preoperative biliary drainage before pancreaticoduodenectomy. Might be needed if the biliary tract in obstructed and the surgery cannot be scheduled in near future.

Intervention type: PROCEDURE
Intervention: Preoperative biliary drainage
Description: Preoperative biliary drainage before pancreaticoduodenectomy. Might be needed if the biliary tract in obstructed and the surgery cannot be scheduled in near future.
Study: NCT00323141

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventralex versus Leight Weight Vypro II prothesis
Description: Ventralex and Leight Weight Vypro II prothesis are compared.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventralex versus Leight Weight Vypro II prothesis
Description: Ventralex and Leight Weight Vypro II prothesis are compared.
Study: NCT04528641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRAd-COV2
Description: Single intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRAd-COV2
Description: Single intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRAd-COV2
Description: Single intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRAd-COV2
Description: Single intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRAd-COV2
Description: Single intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRAd-COV2
Description: Single intramuscular administration.
Study: NCT00871910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
Study: NCT00446979

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC 781
Description: UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
Study: NCT01460173

Intervention type: OTHER
Group type: OTHER
Intervention: Divided Attention Steering Simulator (DASS)
Description: Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).

Intervention type: OTHER
Group type: OTHER
Intervention: Divided Attention Steering Simulator (DASS)
Description: Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).
Study: NCT00446979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC 781
Description: UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
Study: NCT03836625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CareConekta
Description: CareConekta is a smartphone app that uses the phone's GPS to prospectively characterize mobility and allow for intervening in real-time. CareConekta uses the phone's built-in GPS system to record location coordinates.
Study: NCT01420861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758
Description: two GTx 758 tablets per day
Study: NCT03636555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin will be given in an intranasal spray (Syntocinon Spray) twice daily (10 insufflations, 1.0 mL, 40 IU/dose) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution (contained all the ingredients in Syntocinon Spray except for oxytocin) will be given as an intranasal spray twice daily (10 insufflations, 1.0 mL/dose) for 12 weeks
Study: NCT03479229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geneveve Treatment
Description: The active treatment group will receive a treatment dose of 90 J/cm\^2

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Treatment
Description: The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm\^2.
Study: NCT01247324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab-matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a-matching placebo
Study: NCT04154475

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yogurt diet
Description: 500 g yogurt/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dairy diet
Description: 500 g non-yogurt dairy products

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard diet
Description: 500 g soya-yogurt
Study: NCT04076540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4041
Description: Administration by Oral syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration by Oral syringe
Study: NCT00884546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Capsule, Oral, Once daily, 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-833923
Description: Capsule, Oral, Once daily, 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-833923
Description: Capsule, Oral, Once daily, 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Capsule, Oral, Once daily, 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Capsule, Oral, Once a week, 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Powder, IV, On days 1, 4, 8, 11, 6 months
Study: NCT02893319

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feeding and growth differences, 5oz vs 8oz bottle
Description: Group A: 5oz bottle Group B: 8oz bottle

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feeding and growth differences, 5oz vs 8oz bottle
Description: Group A: 5oz bottle Group B: 8oz bottle
Study: NCT00498940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimization Testing
Description: Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimization Testing
Description: Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary Biventricular Pacing
Description: Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
Study: NCT01244841

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fast post MI care
Description: All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
Study: NCT01350999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-acid ethyl esters 90 (TAK-085)
Description: Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-acid ethyl esters 90 (TAK-085)
Description: Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid-ethyl (EPA)
Description: EPA-E capsules
Study: NCT00668148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: Ewing's Sarcoma/PNET~10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: Rhabdomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: Leiomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: Adipocytic sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: Synovial sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.
Study: NCT02291146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LA Sprouts intervention
Description: see arm 1 description
Study: NCT03522298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxalisib (GDC-0084)
Description: Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.
Study: NCT00380055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation Services
Description: Navigators (community health workers) identify and assist in overcoming barriers to appropriate cancer care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation Services
Description: Navigators (community health workers) identify and assist in overcoming barriers to appropriate cancer care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer education
Description: Community health workers provide cancer education appropriate for Medicare participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer education
Description: Community health workers provide cancer education appropriate for Medicare participants.
Study: NCT02954107

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: 24h-EEG + video

Intervention type: OTHER
Intervention: Neuropsychological tests

Intervention type: OTHER
Intervention: Neuropsychological tests
Study: NCT00215111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate, reduced glycemic load, and a control diet
Study: NCT02719548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft edge oval - Hard oval - Modified PF breast shield
Description: Treatment order:~1. soft-edge oval breast shield~2. Hard oval breast shield~3. modified PersonalFit breast shield

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified PF breast shield - Soft edge oval - Hard oval
Description: 1. modified PersonalFit breast shield~2. soft-edge oval breast shield~3. Hard oval breast shield

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hard oval - Soft edge oval - Modified PF breast shield
Description: 1. Hard oval breast shield~2. soft-edge oval breast shield~3. modified PersonalFit breast shield
Study: NCT01552070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver
Description: Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without recruit maneuver
Description: After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.